论文部分内容阅读
目的 探讨以雷贝拉唑为主和以法莫替丁为主的三联疗法对糜烂性食管炎(EO)的疗效。方法 将95例内镜证实Ⅰ、Ⅱ级食管炎患者随机分为两组。雷贝拉唑组53 例,予以雷贝拉唑20mg,每日1 次口服;法莫替丁组42例,予以法莫替丁20mg,每日2次口服,两组均同时餐前口服促胃肠动力药及餐后口服胃粘膜保护剂。分别于治疗2、4及8周观察烧心、反酸、胸痛等症状疗效,并于8周后复查胃镜,观察镜下愈合率。结果 治疗2 周,雷贝拉唑组症状改善积分较法莫替丁组明显下降(P < 0. 05),治疗8 周症状消失,总有效率雷贝拉唑组为92. 45%,法莫替丁组为80 .95%。两组比较有明显差异(P<0.05)。两组在内镜下不同等级食管炎的疗效,对Ⅱ级食管炎,雷贝拉唑组优于法莫替丁组(P<0. 05),而对Ⅰ级食管炎两组疗效差别无显著性意义(P>0 .05)。结论 雷贝拉唑为主三联疗法是治疗EO的一线药物。法莫替丁为主的三联疗法是治疗轻度EO患者的有效药物。
Objective To investigate the curative effect of triple therapy with predominant rabeprazole and famotidine on erosive esophagitis (EO). Methods Ninety-five patients with endometrial proven grade Ⅰ and Ⅱ esophagitis were randomly divided into two groups. Rabeprazole group 53 cases, given rabeprazole 20mg, 1 times a day orally; famotidine group 42 cases, to be famotidine 20mg, 2 times a day orally, both groups were simultaneously oral fasting Gastrointestinal motility drug and postprandial oral gastric mucosal protective agent. The curative effect of heartburn, acid reflux, chest pain and other symptoms were observed at 2, 4 and 8 weeks after treatment. Gastroscopy was performed after 8 weeks and the healing rate under the microscope was observed. Results After treatment for 2 weeks, the symptom improvement scores of rabeprazole group were significantly lower than those of famotidine group (P <0.05), the symptoms disappeared after 8 weeks of treatment, and the total effective rate of rabeprazole group was 92.45% Mometasine group was 80.95%. There was significant difference between the two groups (P <0.05). The efficacy of endoscopic esophagitis with different grades of esophagitis was superior to that of famotidine in grade Ⅱ esophagitis and rabeprazole (P <0.05), while the difference was not significant between the two groups Significant significance (P> 0.05). Conclusions Rabeprazole-based triple therapy is the first-line drug for the treatment of EO. Famotidine-based triple therapy is an effective drug for the treatment of mild EO.